Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

AIFU vs ADGM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AIFU Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–3 Matrix Metrics)

AIFU Overall Winner 6-Pillar Tally: AIFU 2 – 2 ADGM (2 Tie) Matrix Metrics: AIFU 6 – 3 ADGM

As of Nov 17, 2026, AIFU Inc. Class A Ordinary Share (AIFU) is the stronger overall head-to-head candidate over Adagio Medical Holdings, Inc (ADGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality). AIFU carries a Unified Composite Score of 58.5/100 (HOLD) at $9.76 (18.8x Forward P/E, -220.0% operating margin), whereas ADGM carries 32.4/100 (SELL) at $1.57 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: AIFU earns the overall head-to-head edge with a stronger Unified Composite Score (58.5/100 HOLD vs. ADGM 32.4/100 SELL) and -7.07β · 88% Vol risk profile, whereas ADGM leads top-line expansion (+75.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AIFU vs ADGM
AIFU NASDAQ Head-to-Head Winner
AIFU Inc. Class A Ordinary Share
Insurance Agents, Brokers & Service
$9.76
-0.85% 1D
Market Cap $590.2M
TTM Revenue $485M
Forward P/E 18.8x
Beta / 30D Vol -7.07β · 88% Vol
Unified Composite Score
58.5 / 100 HOLD
Tech 79.0 Fund 63.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $9.51 · SMA50: $10.40
ADGM NASDAQ
Adagio Medical Holdings, Inc Common Stock
Surgical & Medical Instruments & Apparatus
$1.57
-2.48% 1D
Market Cap $1.8M
TTM Revenue $137,000
Forward P/E N/M
Beta / 30D Vol 48.13β · 9676% Vol
Unified Composite Score
32.4 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.7% over 20 days), RSI 72
RSI-14: 71.9 · SMA20: $0.69 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (AIFU 2 – 2 ADGM)

Columns: Metric · AIFU · ADGM
1. Valuation Multiples AIFU
Forward P/E 18.8x N/M
Trailing P/E 20.4x N/M
PEG Ratio N/M N/M
EV / Revenue 1.2x 12.9x
2. Growth & Scale ADGM
Revenue Growth (YoY) -24.0% +75.6%
Earnings Growth (YoY) -96.8% +0.0%
TTM Revenue (USD) $485M $137,000
Market Cap $590.2M $1.8M
3. Profitability & Quality AIFU
Gross Margin 50.9% -65.0%
Operating Margin -220.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -112.3% -657.8%
4. Balance Sheet & Cash Flow ADGM
Cash Generation (TTM) -$1.06B EBITDA -$19M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $25.31 Book/Sh · -112.3% ROE -657.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 142.0% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance Brokers Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AIFU (6) vs ADGM (3)
Institutional Metric AIFU ADGM Criterion Row Edge
Market Capitalization
Scale
$590.2M $1.8M Larger Scale AIFU
Trailing P/E Ratio
Valuation
20.4x N/M Lower Multiple AIFU
Forward P/E Ratio
Valuation
18.8x N/M Lower Multiple AIFU
Revenue Growth (YoY)
Growth
-24.0% +75.6% Higher Growth ADGM
Operating Margin (TTM)
Profitability
-220.0% 0.0% Higher Margin ADGM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-112.3% -657.8% Higher ROE AIFU
52-Week Range Position
Momentum
15% ($1–$60) 67% ($0–$2) Stronger Trend ADGM
Beta / 30D Volatility
Risk Regime
-7.07β · 88% Vol 48.13β · 9676% Vol Lower Realized Risk AIFU
Unified Institutional Score
Composite Signal
58.5 / 100 (HOLD) 32.4 / 100 (SELL) Higher Composite AIFU
Trailing 12M Revenue (USD)
Operating Scale
$485M $137,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.9% -65.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · 12.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.06B EBITDA ($25.31 Book/Sh · -112.3% ROE) -$19M EBITDA (-657.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADGM +1220.04 pp
AIFU: -11.71% · ADGM: +1208.33%
3M Horizon ADGM +170.37 pp
AIFU: -21.95% · ADGM: +148.42%
6M Horizon AIFU +263.67 pp
AIFU: +351.69% · ADGM: +88.02%
1Y Horizon AIFU +43.22 pp
AIFU: +143.3% · ADGM: +100.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AIFU vs ADGM. Trailing 12-month operating profitability (AIFU -220.0% vs ADGM 0.0%) and valuation multiples (AIFU 18.8x vs ADGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AIFU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$485M
Gross Margin50.9%
Op. Margin-220.0%
ROE / Fwd P/E-112.3% · 18.8x
ADGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$137,000
Gross Margin-65.0%
Op. Margin0.0%
ROE / Fwd P/E-657.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AIFU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 142.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIFU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AIFU Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $590.2M market capitalization and -220.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ADGM Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AIFU vs ADGM Key Questions & Quantitative Answers

As of Nov 17, 2026, AIFU Inc. Class A Ordinary Share (AIFU) is the stronger overall head-to-head candidate over Adagio Medical Holdings, Inc (ADGM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality). AIFU carries a Unified Composite Score of 58.5/100 (HOLD) at $9.76 (18.8x Forward P/E, -220.0% operating margin), whereas ADGM carries 32.4/100 (SELL) at $1.57 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: AIFU earns the overall head-to-head edge with a stronger Unified Composite Score (58.5/100 HOLD vs. ADGM 32.4/100 SELL) and -7.07β · 88% Vol risk profile, whereas ADGM leads top-line expansion (+75.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

ADGM leads the Growth & Scale pillar: AIFU posts -24.0% YoY revenue growth and -96.8% YoY earnings growth on $485M TTM revenue (50.9% gross margin, -220.0% operating margin), compared with ADGM at +75.6% YoY revenue growth and +0.0% YoY earnings growth on $137,000 TTM revenue (-65.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, AIFU generates $485M in USD-normalized revenue versus $137,000 for ADGM. In operating R&D and SG&A reinvestment, AIFU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADGM.

AIFU screens cheaper on headline valuation multiples. AIFU trades at 18.8x Forward P/E, 20.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported EBITDA margin), whereas ADGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AIFU (-112.3% ROE) versus ADGM (-657.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AIFU carries 142.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.07β · 88% Vol realized risk). By comparison, ADGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (48.13β · 9676% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.